Classifications: hormone; gonadotropin-releasing hormone (gnrh) antagonist; Therapeutic: gnrh antagonist
Pregnancy Category: X
250 mcg/0.5 mL syringe
Ganirelix is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses pituitary gonadotropins and sex hormones.
It prevents LH surges in reproductive protocols, and causes shrinkage of uterine fibroids.
Prior hypersensitivity to ganirelix, LHRH, or other LHRH analogs, mannitol hypersensitivity; ovarian cyst; primary ovarian
failure; pregnancy (category X), lactation.
History of current allergic disorders (e.g., asthma, hay fever, urticaria, eczema) or a history of allergic reactions to medications;
renal/hepatic dysfunction; endocrine disorders; alcohol consumption.
Route & Dosage
Adult: SC After initiating follicle-stimulating hormone (FSH) therapy on day 2 or 3 of the cycle, give 250 mcg once daily during the
- Note: The packaging of the product, Antagon, contains natural rubber latex which may cause allergic reactions.
- Inject SC into the abdomen around the umbilicus or into the upper thigh.
- Rotate injection sites.
- Store at 5°30° C (59°86° F) and protect from light.
Adverse Effects (≥1%)CNS:
Abdominal pain, nausea. Endocrine:
Ovarian hyperstimulation syndrome
Injection site reaction. Urogenital:
No clinically significant interactions established.
91% from SC site. Peak:
1 h. Distribution:
81% protein bound. Elimination:
75% in feces; 22% in urine. Half-Life:
Assessment & Drug Effects
- Exercise caution with patients with hypersensitivity to GnRH or with known allergic disorders (e.g., asthma, hay fever). These
patients should be carefully monitored after the first injection for S&S of an anaphylactic reaction.
- Lab tests: Monitor baseline and periodic CBC with differential, and periodic total bilirubin.
Patient & Family Education
- Report menstrual disorders (e.g., spotting, frank vaginal bleeding) to physician.
- Notify physician immediately if you think you are pregnant.